Articles

MHRA decisions show prescription-only medicine advertising risk across homepages, print, email, SMS and launch waitlists.

MHRA repeats botulinum toxin safety warnings, including a four-week symptom window, as our weekly scan finds no other target-sector regulatory change.

A new claims study assessed GLP-1 continuation in early pregnancy, finding no definitive risk increase but wide uncertainty around several important outcomes.

A UK survey of 919 cosmetic Botox patients linked treatment setting, injector role and undisclosed products with different odds of reported adverse events.

A source-led guide to registration, governance, remote prescribing, medicine supply, advertising and Northern Ireland pharmacy regulation.

A UK primary-care cohort found greater one-year HbA1c and weight reductions with semaglutide than dulaglutide, with comparable safety overall.

Scotland cannot produce consistent national data on aesthetic complications. Our weekly scan tracks what changed across six UK regulatory sources this week.

The MHRA's Criminal Enforcement Unit is investigating unlicensed botulinum toxin products after a spike in hospital admissions. This enforcement analysis separates the authorised-product safety update from the criminal investigations.

A genetic study linked GLP-1 receptor activation to lower depression and bipolar risk. MHRA and EMA reviews found no causal link to suicidal thoughts.

Scotland's non-surgical procedures framework starts being built on 22 July 2026. What the commencement order activates — and what stays on hold until 2027.

New observational evidence found no overall increase in ocular disorders, but uncertainty and the MHRA semaglutide warning still matter for clinics.

Weekly regulatory scan: CQC reports a 134% rise in private CBPM prescribing and records what changed across six UK regulatory sources.

The MHRA approved Wegovy to treat MASH liver disease. This update explains what it means for private clinics prescribing semaglutide.

Research on safety risks in online pharmacy weight-loss prescribing and how it connects to GPhC enforcement.

A Nature Medicine review of 56 trials covering semaglutide and tirzepatide, with implications for UK clinic prescribing.

Sir Mike Richards' appointment as preferred CQC Chair and what his regulatory track record signals for private clinics.

The first national workforce mapping study and what it adds to the case for cosmetic-procedure licensing.

A GPhC review found weak risk assessments and inconsistent BMI checks in online pharmacies prescribing weight-loss medicines.

New prevalence evidence on UK GLP-1 use and the implications for advertising enforcement and pharmacy safeguards.

A sourced guide to Section 180, Scotland's law, the proposed three-tier system and the current UK licensing position.

The ASA ruled against Juniper and Voy over Black Friday promotions for prescription-only weight-loss medicines.

Recent ASA rulings reveal a recurring pattern in weight-loss advertising for prescription-only medicines.

The ASA's monitoring found roughly 900 prescription-only medicine advertising violations from 38 advertisers.

What Section 180 says, who it affects and where the cosmetic-procedure licensing scheme currently stands.